Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment.

Nucleic Acid Ther · 2022 · PMC9416542 · PMID 35263186

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A total of four phase 1 and phase 2 studies documented highly significant clinical and endoscopic benefit of mongersen in patients with active Crohn's disease [ 24 , 25 , 27 , 29 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.